Overview

Phase II Trial of CD24Fc for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Status:
Completed

Trial end date:
2021-05-18

Target enrollment:

Participant gender:

Summary

This is a multicenter prospective phase IIa dose escalation and phase IIa expansion cohort clinical trial designed to evaluate the safety and tolerability of CD24Fc for acute GVHD prophylaxis.

Phase:

Phase 2

Details

Lead Sponsor:

OncoImmune, Inc.

Collaborators:

Barbara Ann Karmanos Cancer Institute
Indiana University School of Medicine
National Cancer Institute (NCI)
Ohio State University
University of Michigan Cancer Center
University of Michigan Rogel Cancer Center

Treatments:

Methotrexate
Tacrolimus